We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breast Tumors That Display Kataegis Have a Better Prognosis

By LabMedica International staff writers
Posted on 12 Jul 2016
Print article
Image: In kataegis, multiple mutations cluster in a few hotspots in a cancer genome. Here, cytosine (C) bases are commonly substituted with thymine (T) in the DNA strand (Photo courtesy of Matteo D’Antonio, University of California, San Diego).
Image: In kataegis, multiple mutations cluster in a few hotspots in a cancer genome. Here, cytosine (C) bases are commonly substituted with thymine (T) in the DNA strand (Photo courtesy of Matteo D’Antonio, University of California, San Diego).
Breast tumors that display kataegis, a state of hypermutation that is localized to only a few genomic regions, are not highly invasiveness, and patients with cancers that possessing this marker have a good prognosis.

Kataegis is a mutational process observed in approximately 55% of breast tumors that results in hypermutation in localized genomic regions. Investigators at the University of California, San Diego (USA) used whole-genome sequence data of 97 tumors to examine the distribution of kataegis loci.

The data they obtained revealed that these somatic mutations were over-represented on chromosomes 8, 17, and 22 and depleted on chromosomes 2, 9, and 16 and were enriched in regions containing genes and functional regulatory elements. Genes in the vicinity of kataegis loci were less likely to be aberrantly expressed than genes that were located farther away. Breast cancers that contained kataegis had a transcriptome-wide expression signature that was consistent with low invasive potential and enabled the kataegis status of a tumor to be predicted using RNA sequencing (RNA-seq) data.

The investigators exploited the kataegis expression signature to predict kataegis status in 412 breast cancers with transcriptome but not whole-genome sequence data and showed that kataegis loci were enriched in high-grade, HER2+ tumors in patients diagnosed with breast cancer at an older age and who had a later age at death.

“We do not know what causes kataegis, and before this study not much was known about its functional importance at the molecular or clinical level,” said senior author Dr. Kelly Frazer, professor of pediatrics at the University of California, San Diego. “We have now found that kataegis is associated with a good prognosis for patients with breast cancer. Kataegis status might also be helpful in determining a patient’s treatment options, but there is a long way to go before kataegis status could be used in the clinic.”

The paper on kataegis in breast tumors was published in the June 30, 2016, online edition of the journal Cell Reports.

Related Links:
University of California, San Diego


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.